Text Size

A Study to Evaluate the Effectiveness and Safety of TAK-491(Azilsartan Medoxomil) and Chlorthalidone Combined in One Tablet (40/12.5 and 40/25 mg) in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure on Treatment With TAK-491 40 mg Alone

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Takeda Global Research & Development Center, Inc. ( Takeda Global Research & Development Centre (Europe) Ltd. )
ClinicalTrials.gov Identifier:
NCT01456169
First received: October 18, 2011
Last updated: January 18, 2013
Last verified: January 2013
History of Changes
  Purpose

The purpose of this study is to evaluate the efficacy and safety of the fixed dose combinations of azilsartan medoxomil plus chlorthalidone, once daily (QD), in participants with grades 2 or 3 essential hypertension who do not reach target blood pressure following treatment with 40 mg azilsartan medoxomil monotherapy after 4 weeks.


Condition Intervention Phase
Essential Hypertension
 Drug: Azilsartan medoxomil
Drug: Azilsartan medoxomil and chlorthalidone
 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase-3 Randomized, Double-Blind, Efficacy and Safety Study Evaluating the Fixed Dose Combinations of TAK-491 Plus Chlorthalidone (40/12.5 mg and 40/25 mg) in Subjects With Grades 2 or 3 Essential Hypertension, Who Do Not Achieve Target Blood Pressure Following Treatment With TAK-491 40 mg Monotherapy

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Takeda Global Research & Development Center, Inc.:

Primary Outcome Measures:
  • Change from baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure [ Time Frame: Baseline and Week 8. ] [ Designated as safety issue: No ]
    The change between trough systolic blood pressure measured at final visit or week 8 relative to baseline. Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.


Secondary Outcome Measures:
  • Change from baseline to Week 8 in Trough, Sitting, Clinic Diastolic Blood Pressure [ Time Frame: Baseline and Week 8. ] [ Designated as safety issue: No ]
    The change between trough diastolic blood pressure measured at final visit or week 8 relative to baseline Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.

  • Change from Baseline to Week 8 in Trough (22 to 24 hours after dosing) Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring [ Time Frame: Baseline and Week 8. ] [ Designated as safety issue: No ]
    The change in trough systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.

  • Change from Baseline to Week 8 in Trough Diastolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring [ Time Frame: Baseline and Week 8. ] [ Designated as safety issue: No ]

    The change in trough diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The trough is the average of all measurements recorded from 22 to 24 hours after dosing.

    Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night.


  • Change From Baseline to Week 8 in the 24-hour Mean Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring [ Time Frame: Baseline and Week 8. ] [ Designated as safety issue: No ]
    The change in 24-hour mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

  • Change From Baseline to Week 8 in the 24-hour Mean Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring [ Time Frame: Baseline and Week 8. ] [ Designated as safety issue: No ]
    The change in 24-hour mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 24-hour mean is the average of all measurements recorded for 24 hours after dosing.

  • Change From Baseline to Week 8 in the Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring [ Time Frame: Baseline and Week 8. ] [ Designated as safety issue: No ]
    The change in daytime (6am to 10pm) mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

  • Change From Baseline to Week 8 in the Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring [ Time Frame: Baseline and Week 8. ] [ Designated as safety issue: No ]
    The change in daytime (6am to 10pm) mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Daytime mean is the average of all measurements recorded between the hours of 6 am and 10 pm.

  • Change From Baseline to Week 8 in the Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring [ Time Frame: Baseline and Week 8. ] [ Designated as safety issue: No ]
    The change in nighttime (12am to 6am) mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

  • Change From Baseline to Week 8 in the Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure, as Measured by Ambulatory Blood Pressure Monitoring [ Time Frame: Baseline and Week 8. ] [ Designated as safety issue: No ]
    The change in nighttime (12am to 6am) mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. Nighttime mean is the average of all measurements recorded between the hours of 12 am and 6 am.

  • Change From Baseline to Week 8 in the Mean Systolic Blood Pressure at 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring [ Time Frame: Baseline and Week 8. ] [ Designated as safety issue: No ]
    The change in the 12-hour mean systolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

  • Change From Baseline to Week 8 in the Mean Diastolic Blood Pressure at 0 to 12 Hours After Dosing, as Measured by Ambulatory Blood Pressure Monitoring [ Time Frame: Baseline and Week 8. ] [ Designated as safety issue: No ]
    The change in the 12-hour mean diastolic blood pressure measured at final visit or week 8 relative to baseline. Ambulatory blood pressure monitoring measures blood pressure at regular intervals throughout the day and night. The 12-hour mean is the average of all measurements recorded in the first 12 hours after dosing.

  • Percentage of Participants Who Achieve a Target Clinic Systolic Blood Pressure at Week 8, as Defined by Trough, sitting clinic Systolic Blood Pressure <140 mm Hg (or <130 mm Hg for patients with diabetes or chronic kidney disease) [ Time Frame: Baseline and Week 8. ] [ Designated as safety issue: No ]
    Percentage of participants who achieve a target clinic systolic blood pressure measured at final visit or week 8, defined as less than 140 mm Hg (or less than 130 mm Hg for patients with diabetes or chronic kidney disease). Systolic blood pressure is the arithmetic mean of the 3 trough sitting systolic blood pressure measurements.

  • Percentage of Participants Who Achieve a Target Clinic Diastolic Blood Pressure at Week 8, Defined as Trough, sitting, clinic Diastolic Blood Pressure <90 mm Hg (or <80 mm Hg for patients with diabetes or chronic kidney disease) [ Time Frame: Baseline and Week 8. ] [ Designated as safety issue: No ]
    Percentage of participants who achieve a target clinic diastolic blood pressure measured at final visit or week 8, defined as less than 90 mm Hg (or less than 80 mm Hg for patients with diabetes or chronic kidney disease). Diastolic blood pressure is the arithmetic mean of the 3 trough sitting diastolic blood pressure measurements.

  • Percentage of Participants Who Achieve Both Clinic Systolic and Diastolic Blood Pressure Targets at Week 8 [ Time Frame: Baseline and Week 8. ] [ Designated as safety issue: No ]
    Percentage of participants who achieve both clinic systolic and diastolic blood pressure targets measured at final visit or week 8, defined as less than 140 mm Hg (or less than 130 mm Hg for patients with diabetes or chronic kidney disease) for systolic AND less than 90 mm Hg (or less than 80 mm Hg for patients with diabetes or chronic kidney disease) for diastolic. Systolic/ diastolic blood pressure is based on the arithmetic mean of the 3 trough sitting systolic/diastolic blood pressure measurements.


Enrollment: 395
Study Start Date: January 2012
Study Completion Date: January 2013
Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Azilsartan medoxomil 40 mg QD Drug: Azilsartan medoxomil
Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks.
Other Names:
  • TAK-491
  • TAK-491CLD
  • EDARBI
Experimental: Azilsartan medoxomil 40 mg/chlorthalidone 12.5 mg QD Drug: Azilsartan medoxomil and chlorthalidone
Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks.
Other Names:
  • TAK-491
  • TAK-491CLD
  • EDARBI
Experimental: Azilsartan medoxomil 40 mg/chlorthalidone 25 mg QD Drug: Azilsartan medoxomil and chlorthalidone
Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks.
Other Names:
  • TAK-491
  • TAK-491CLD
  • EDARBI

Detailed Description:

This study is designed to compare the antihypertensive effect and the safety of two fixed-dose combinations of azilsartan medoxomil plus chlorthalidone (40/12.5 and 40/25 mg) during 8 weeks of treatment with azilsartan medoxomil 40 mg plus placebo.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

At Screening

  1. The participant has grade 2-3 essential hypertension which is not adequately controlled, as defined by mean, trough, sitting, clinic systolic blood pressure (SBP):

    • ≥160 to ≤180 mm Hg in participants who have not received any antihypertensive medication in the 14 days prior to Visit 1.
    • ≥150 to ≤170 mm Hg in participants taking 1 antihypertensive medication at Visit 1.
    • ≥140 to ≤160 mm Hg in participants taking 2 antihypertensive medications at Visit 1.
  2. The participant has clinical laboratory test results (clinical chemistry, hematology, and complete urinalysis) within the reference range for the testing laboratory or the investigator does not consider the results to be clinically relevant for precluding entry in to the study in this hypertensive population.
  3. The participant is willing to discontinue current antihypertensive medications.
  4. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
  5. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.
  6. The participant is a man or woman and aged 18 years or older, inclusive.

  7. A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to routinely use adequate contraception from signing of the informed consent through 30 days after the last study drug dose. NOTE: Women NOT of childbearing potential are defined as those who have been surgically sterilized (hysterectomy, bilateral oophorectomy, tubal ligation [performed more than one 1 year prior to Screening]) or who are postmenopausal (defined as at least 1 year since last regular menses).

    Post-placebo run-in:

  8. The participant must have a post-placebo run-in, 24-hour mean SBP by ambulatory blood pressure monitoring (ABPM) of 140-175 mm Hg inclusive, and a clinic SBP measurement of 160 to 190 mm Hg inclusive (determined by the mean of 3 sitting, trough, measurements on Day -29) to qualify for entry in to the 4 week single-blind TAK-491 40 mg monotherapy treatment period.

    Post-4 week, single-blind TAK-491 40 mg monotherapy treatment:

  9. The participant does not achieve target blood pressure (defined as clinic SBP ≥140 mm Hg as determined by the mean of 3 sitting, trough, measurements) following 4 weeks single-blind treatment with TAK-491 40 mg monotherapy at Day -1, prior to randomization to double-blind treatment.

Exclusion Criteria:

At Screening

  1. The participant has clinic diastolic blood pressure (DBP) >110 mm Hg.
  2. The participant's 3 SBP measurements differ by more than 15 mm Hg (confirmed by a second set of three measurements).
  3. The participant has received any investigational compound within 30 days prior to Screening or is currently participating in another investigational study. NOTE: Participants participating in observational studies (per local definition) may enter Screening provided that the last intervention or invasive procedure was >30 days prior to Visit 1.
  4. The participant has been randomized/enrolled in a previous TAK-491 or TAK-491CLD study. NOTE: This criterion does not apply to participants who entered screening or placebo run-in in another TAK-491 or TAK-491CLD study but were not randomized/enrolled.
  5. The participant is a study site employee or is in a dependent relationship with a study site employee who is involved in conduct of this study (e.g., spouse, parent, child, sibling) or may consent under duress.
  6. The participant is currently treated with more than 2 antihypertensive medications.
  7. The participant works a night (third) shift (defined as 11 PM [2300] to 7 AM [0700]).
  8. The participant has an upper arm circumference <24 cm or >42 cm.
  9. The participant has secondary hypertension of any etiology (e.g., renovascular disease, pheochromocytoma, Cushing's syndrome).
  10. The participant has any history of myocardial infarction, heart failure, unstable angina, coronary artery bypass graft, percutaneous coronary intervention, hypertensive encephalopathy, cerebrovascular accident, persistent or permanent atrial fibrillation or transient ischemic attack.
  11. The participant has clinically significant cardiac conduction defects (e.g., third-degree atrioventricular block, sick sinus syndrome).
  12. The participant has hemodynamically significant left ventricular outflow obstruction due to aortic valvular disease or hypertrophic cardiomyopathy.
  13. The participant has severe renal dysfunction or disease [based on estimated glomerular filtration rate (eGFR) <30 mL/min/1.73m2 at screening], prior renal transplantation or nephrotic syndrome (defined as a urinary albumin/creatinine ratio >2000 mg/g at Screening).
  14. Participant has known hemodynamically significant bilateral renal artery stenosis or unilateral disease in a single kidney.
  15. The participant has a history of cancer that has not been in remission for at least 5 years prior to the first dose of single-blind TAK-491 monotherapy study drug. (This criterion does not apply to those participants with basal cell or Stage 1 squamous cell carcinoma of the skin).
  16. The participant has poorly-controlled type 1 or 2 diabetes mellitus (hemoglobin A1c [HbA1c] >8.5%) at Screening.
  17. The participant has hypokalemia or hyperkalemia (defined as serum potassium outside of the normal reference range of the central laboratory) at Screening.
  18. The participant has an alanine aminotransferase or aspartate aminotransferase level >2.5 times the upper limit of normal, active liver disease, or jaundice at Screening.
  19. The participant has any other known serious disease or condition that would compromise safety, might affect life expectancy, or make it difficult to successfully manage and follow the participant according to the protocol.
  20. The participant has a history of hypersensitivity or allergies to angiotensin II receptor blockers (ARB) or thiazide-type diuretics or other sulfonamide-derived compounds.
  21. The participant has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse per local guidelines within the past 2 years.
  22. The participant is required to take excluded medications at any point during the study.

  23. If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 1 month after participating in this study; or intending to donate ova during such time period.

    Post-placebo run-in period

  24. The participant has a clinic SBP >190 mm Hg and DBP >115 mm Hg.
  25. The participant is noncompliant (<70% or >130%) with study medication during the placebo run-in period.

  26. The participant has a 24-hour mean eligibility ABPM reading of insufficient quality (as described in Appendix E).

    Post-single-blind TAK-491 40 mg treatment period

  27. The participant has a clinic SBP >180 mm Hg and DBP >110 mm Hg.
  28. The participant is noncompliant (<70% or >130%) with study medication during the TAK-491 40 mg single-blind treatment period.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01456169

  Show 95 Study Locations
Sponsors and Collaborators
Takeda Global Research & Development Centre (Europe) Ltd.
Investigators
Study Director: Medical Director, Clinical Science Takeda Global Research & Development Centre, Ltd.
  More Information

Additional Information:
FDA Safety Alerts and Recalls  This link exits the ClinicalTrials.gov site
EDARBYCLOR Package Insert  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Takeda Global Research & Development Center, Inc. ( Takeda Global Research & Development Centre (Europe) Ltd. )
ClinicalTrials.gov Identifier: NCT01456169     History of Changes
Other Study ID Numbers: TAK-491CLD_307, 2011-000220-16, U1111-1119-4743, 11-028, NL36272.072.11
Study First Received: October 18, 2011
Last Updated: January 18, 2013
Health Authority: Spain: Spanish Agency of Medicines
Estonia: The State Agency of Medicine
European Union: European Medicines Agency
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Federal Institute for Drugs and Medical Devices
Italy: The Italian Medicines Agency
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Lithuania: State Medicine Control Agency - Ministry of Health
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Slovakia: State Institute for Drug Control
Sweden: Medical Products Agency
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Bulgaria: Bulgarian Drug Agency
Czech Republic: State Institute for Drug Control
Hungary: National Institute of Pharmacy
Serbia and Montenegro: Agency for Drugs and Medicinal Devices
United States: Food and Drug Administration

Keywords provided by Takeda Global Research & Development Center, Inc.:
High Blood Pressure
Drug Therapy

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases
Chlorthalidone
Sodium Chloride Symporter Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
 Pharmacologic Actions
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Diuretics
Natriuretic Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 19, 2013